## COVID-19 Clinical effort 

Current worldwide research clinical efforts against COVID-19. Drug candidates suggested from these studies are provided here and updated daily. We also include our initial data anlaysis results from previous antiviral drug discovery studies to facilitate such efforts. We seek experts' opinions and efforts to further validate these candidates, which will be continuously re-defined and selected based on their prior data on COVID-19 related viruses and newly generated data on COVID-19.

### COVID-19 Clinical Trials registration list

A list of registered clinical trials for COVID-19 infection is collected in the table below. This data was initially collected from [Biocentury](https://www.biocentury.com/article/304368) and sorted based on registration date. Additionally, [dimensions.ai](https://covid-19.dimensions.ai/) provides a full list of clinical trials regarding COVID-19. We will continue to provide updated clinical trial information involving potential drug candidates.

| Registration number                                          | Intervention                                                 | Type                      | Registration date |
| ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------- | ----------------- |
| [ChiCTR2000029308](http://www.chictr.org.cn/showprojen.aspx?proj=48684) | Lopinavir/ritonavir; interferon α 2b                         | Antiviral                 | 2020/1/23         |
| [ChiCTR2000029386](http://www.chictr.org.cn/showprojen.aspx?proj=http://www.chictr.org.cn/showprojen.aspx?proj=48777) | Lopinavir/ritonavir; methylprednisolone; interferon α        | Antiviral; Corticosteroid | 2020/1/28         |
| [ChiCTR2000029387](http://www.chictr.org.cn/showprojen.aspx?proj=48782) | Lopinavir/ritonavir; ribavirin; interferon α-1b              | Antiviral                 | 2020/1/28         |
| [NCT04244591](https://clinicaltrials.gov/ct2/show/NCT04244591) | Methylprednisolone                                           | Corticosteroid            | 2020/1/28         |
| [ChiCTR2000029468](http://www.chictr.org.cn/showprojen.aspx?proj=48919) | Lopinavir/ritonavir; emtricitabine/tenofovir alafenamide fumarate | Antiviral                 | 2020/2/2          |
| [ChiCTR2000029496](http://www.chictr.org.cn/showprojen.aspx?proj=48809) | Lopinavir/ritonavir; Novaferon                               | Antiviral                 | 2020/2/3          |
| [ChiCTR2000029539](http://www.chictr.org.cn/showprojen.aspx?proj=48991) | Lopinavir/ritonavir                                          | Antiviral                 | 2020/2/3          |
| [ChiCTR2000029541](http://www.chictr.org.cn/showprojen.aspx?proj=48992) | Darunavir/cobicistat; Lopinavir/ritonavir; thymosin          | Antiviral                 | 2020/2/3          |
| [ChiCTR2000029542](http://www.chictr.org.cn/showprojen.aspx?proj=48968) | Chloroquine                                                  | Antiviral                 | 2020/2/3          |
| [ChiCTR2000029548](http://www.chictr.org.cn/showprojen.aspx?proj=49015) | Baloxavir Marboxil; Favipiravir; Lopinavir/ritonavir         | Antiviral                 | 2020/2/4          |
| [ChiCTR2000029580](http://www.chictr.org.cn/showprojen.aspx?proj=49088) | Ruxolitinib                                                  | Inhibitor                 | 2020/2/5          |
| [NCT04252885](https://clinicaltrials.gov/ct2/show/NCT04252885) | Umifenovir (Arbidol)                                         | Antiviral                 | 2020/2/5          |
| [NCT04255017](https://clinicaltrials.gov/ct2/show/NCT04255017) | Umifenovir (Arbidol); Oseltamivir; Lopinavir/ritonavir       | Antiviral                 | 2020/2/5          |
| [NCT04257656](https://clinicaltrials.gov/ct2/show/NCT04257656) | Remdesivir                                                   | Antiviral                 | 2020/2/6          |
| [ChiCTR200029600](http://www.chictr.org.cn/showprojen.aspx?proj=49042) | Favipiravir, Lopinavir/Ritonavir + alpha-Interferon          | Antiviral                 | 2020/2/6          |
| [ChiCTR2000029853](http://www.chictr.org.cn/showprojen.aspx?proj=49532) | Azvudine                                                     | Antiviral                 | 2020/2/16         |
| [NCT04273529](https://clinicaltrials.gov/ct2/show/NCT04273529) | Thalidomide                                                  | Immunomodulatory agent    | 2020/2/18         |
| [ChiCTR2000030000](http://www.chictr.org.cn/showprojen.aspx?proj=49748) | Ganovo (Danoprevir)/ritonavir; Peginterferon alfa-2a         | Antiviral                 | 2020/2/19         |
| [ChiCTR2000030001](http://www.chictr.org.cn/showprojen.aspx?proj=49723) | Triazavirin                                                  | Antiviral                 | 2020/2/19         |
| [NCT04280588](https://clinicaltrials.gov/ct2/show/NCT04280588) | Fingolimod                                                   | Receptor modulator        | 2020/2/21         |
| [ChiCTR2000030055](http://www.chictr.org.cn/showprojen.aspx?proj=49864) | Dipyridamole                                                 | Inhibitor                 | 2020/2/22         |
| [ChiCTR2000030002](http://www.chictr.org.cn/showprojen.aspx?proj=49738) | Tranilast                                                    | Inhibitor                 | 2020/2/24         |
| [ChiCTR2000030328](http://www.chictr.org.cn/showprojen.aspx?proj=50241) | Acetylcysteine                                               | Mucolytic agent           | 2020/2/28         |
| [ChiCTR2000030535](http://www.chictr.org.cn/showprojen.aspx?proj=49790) | Ebastine                                                     | Antihistamine             | 2020/3/6          |
| [NCT04311177](https://clinicaltrials.gov/ct2/show/NCT04311177) | Losartan                                                     | Receptor blocker          | 2020/3/17         |
| [ChiCTR2000031138](http://www.chictr.org.cn/showprojen.aspx?proj=51416) | Pirfenidone                                                  | Inhibitor                 | 2020/3/22         |
| [NCT04321096](https://clinicaltrials.gov/ct2/show/NCT04321096) | Camostat Mesilate                                            |                           | 2020/3/25         |

---

## Detailed Drug information of current published or ongoing in vitro or clinical studies on COVID-19

The information below is collected from recent research articles, news articles, or clinical reports of COVID-19 studies contributed from various research groups worldwide. The source links or full article download are provided to facilitate your own investigation and research on these molecules. 


| Drug Name             | Structure                                                    | MoA                                                          | Indication                                                   | DrugBank URL                                                 | Anti-2019-nCoV Evidence                          | Reference                                                    |
| --------------------- | ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ | ----------------------------------------------- | ------------------------------------------------------------ |
| Remdesivir            | ![img3](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_remdesivir.png) | RNA  polymerase inhibitor                                    | Anti-Ebola passed Phase III, COVID-19 Phase III              | [DB14761](https://www.drugbank.ca/drugs/DB14761)             | In Vitro Assay, Clinical report, Clinical trial | [7](http://www.xinhuanet.com/english/2020-01/30/c_138742163.htm); [8](https://www.nejm.org/doi/10.1056/NEJMoa2001191); [14](http://clarivate.com.cn/coronavirus-resources/images/Remdesivir.pdf); [15](https://www.nature.com/articles/s41422-020-0282-0); [16](https://clinicaltrials.gov/ct2/show/NCT04257656) |
| Lopinavir             | ![img1](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_lopinavir.png) | Protease inhibitor                                           | Anti-HIV approved, COVID-19                                  | [DB01601](https://www.drugbank.ca/drugs/DB01601)             | Clinical trial                                  | [1](http://www.chictr.org.cn/showprojen.aspx?proj=48684); [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919); [3](http://www.chictr.org.cn/showprojen.aspx?proj=48809); [4](http://www.chictr.org.cn/showprojen.aspx?proj=48991); [5](http://www.chictr.org.cn/showprojen.aspx?proj=48782); [6](http://www.nhc.gov.cn/yzygj/s7652m/202001/7450028ab6084101ae8110f0aaf81271.shtml) |
| Ritonavir             | ![img2](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_ritonavir.png) | Protease inhibitor                                           | Anti-HIV approved, COVID-19                                  | [DB00503](https://www.drugbank.ca/drugs/DB00503)             | Clinical trial                                  | [1](http://www.chictr.org.cn/showprojen.aspx?proj=48684); [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919); [3](http://www.chictr.org.cn/showprojen.aspx?proj=48809); [4](http://www.chictr.org.cn/showprojen.aspx?proj=48991); [5](http://www.nhc.gov.cn/yzygj/s7652m/202001/7450028ab6084101ae8110f0aaf81271.shtml); [6](http://www.chictr.org.cn/showprojen.aspx?proj=48782) |
| Emtricitabine         | ![img13](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_emtricitabine.png) | nucleoside reverse  transcriptase inhibitor                  | Anti-HIV  approved, anti-HBV                                 | [DB00879](https://www.drugbank.ca/drugs/DB00879)             | Clinical trial                                  | [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919)     |
| Tenofovir             | ![img14](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_tenofovir.png) | nucleoside reverse  transcriptase inhibitor                  | Anti-HIV Phase III, anti-HBV                                 | [DB14126](https://www.drugbank.ca/drugs/DB14126)             | Clinical trial                                  | [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919)     |
| Ribavirin             | ![img12](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_ribavirin.png) | viral mRNA and  protein synthesis inhibitor                  | Anti-HCV,  Anti-HBV, Anti-SARS, Anti-influenza, COVID-19     | [DB00811](https://www.drugbank.ca/drugs/DB00811)             | Clinical trial                                  | [5](http://www.chictr.org.cn/showprojen.aspx?proj=48782)     |
| Umifenovir            | ![img5](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_arbidol.png) |                                                              | Influenza approved, COVID-19 Phase 4                         | [DB13609](https://www.drugbank.ca/drugs/DB13609)             | Clinical trial                                  | [9](https://clinicaltrials.gov/ct2/show/NCT04252885); [22](https://clinicaltrials.gov/ct2/show/NCT04255017) |
| Ruxolitinib           | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_ruxolitinib.png) | KInase inhibitor                                             | COVID-19 Phase 0                                             | [DB08877](https://www.drugbank.ca/drugs/DB08877)             | Clinical Trial                                  | [28](http://www.chictr.org.cn/showprojen.aspx?proj=49088)    |
| Favipiravir           | ![img6](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_favipiravir.png) | RNA polymerase inhibitor                                     | Anti-influenza approved, anti-Ebola Phase II                 | [DB12466](https://www.drugbank.ca/drugs/DB12466)             | Clinical trial                                  | [10](http://www.xinhuanet.com/english/2020-02/01/c_138747115.htm); [18](http://www.chictr.org.cn/showprojen.aspx?proj=49042) |
| Darunavir             | ![img10](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_darunavir.png) | Protease inhibitor                                           | Anti-HIV approved                                            | [DB01264](https://www.drugbank.ca/drugs/DB01264)             | Clinical trial                                  | [11](http://www.chictr.org.cn/showprojen.aspx?proj=48992)    |
| Cobicistat            | ![img11](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_cobicistat.png) |                                                              | Anti-HIV approved                                            | [DB09065](https://www.drugbank.ca/drugs/DB09065)             | Clinical trial                                  | [11](http://www.chictr.org.cn/showprojen.aspx?proj=48992)    |
| Methylprednisolone    | ![img9](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_methylprednisolone.png) | Corticosteroid                                               | COVID-19 Phase II, allergic asthma and rheumatic disorders approved | [DB00959](https://www.drugbank.ca/drugs/DB00959)             | Clinical trial                                  | [12](http://www.chictr.org.cn/showprojen.aspx?proj=48777); [13](https://clinicaltrials.gov/ct2/show/NCT04244591) |
| Baloxavir marboxil    | ![img14](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_baloxavirmarboxil.png) | Polymerase inhibitor                                         | anti-influenza approved                                      | [DB13997](https://www.drugbank.ca/drugs/DB13997)             | Clinical trial                                  | [21](http://www.chictr.org.cn/showprojen.aspx?proj=49015)    |
| Oseltamivir           | ![img15](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_oseltamivir.png) | Neuraminidase inhibitor; Sialidase inhibitor                 | anti-influenza approved, COVID-19 Phase III                  | [DB00198](https://www.drugbank.ca/drugs/DB00198)             | Clinical trial                                  | [22](https://clinicaltrials.gov/ct2/show/NCT04255017)        |
| IFN alpha-1b          |                                                              | Immunomodulation                                             | Interferon                                                   |                                                              | Clinical trial                                  | [5](http://www.chictr.org.cn/showproj.aspx?proj=48782); [6](http://www.nhc.gov.cn/yzygj/s7652m/202001/7450028ab6084101ae8110f0aaf81271.shtml) |
| Danoprevir            | ![img17](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_danoprevir.png) | Protease inhibitor                                           | anti-HCV Phase III, COVID-19 Phase 4                         | [DB11779](https://www.drugbank.ca/drugs/DB11779)             | Clinical trial                                  | [23](http://www.chictr.org.cn/showprojen.aspx?proj=49748)    |
| Peginterferon alfa-2a |                                                              | Immunomodulation                                             | HCV approved, COVID-19 Phase 4                               | [DB00008](https://www.drugbank.ca/drugs/DB00008)             | Clinical trial                                  | [23](http://www.chictr.org.cn/showprojen.aspx?proj=49748)    |
| Chloroquine           | ![img4](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_chloroquine.png) |                                                              | Antimalarial approved, anti-HIV phase III, anti-HCV, COVID-19 Phase  4 | [DB14761](https://www.drugbank.ca/drugs/DB14761)             | In Vitro Assay, Clinical trial                  | [7](http://www.xinhuanet.com/english/2020-01/30/c_138742163.htm); [15](https://www.nature.com/articles/s41422-020-0282-0); [17](http://www.chictr.org.cn/showprojen.aspx?proj=48968) |
| Azvudine              | ![img4](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_azuvudine.png) |                                                              | anti-HIV approved                                            | [PubChem 24769759](https://pubchem.ncbi.nlm.nih.gov/compound/Azvudine) | Clinical trial                                  | [19](http://www.chictr.org.cn/showproj.aspx?proj=49532); [20](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140803/) |
| Dipyridamole          | ![img20](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_dipyridamole.png) | Adenosine deaminase and phosphodiesterase inhibitor          | COVID-19 Phase 4; Phase 4 completed for stroke prevention; Phase 4 completed for coronary arteriosclerosis | [DB00975](https://www.drugbank.ca/drugs/DB00975)             | Clinical Trial                                  | [24](http://www.chictr.org.cn/showprojen.aspx?proj=49864); [25](https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1.full.pdf) |
| Thalidomide           | ![img23](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_thalidomide.png) |                                                              | COVID-19 Phase 2;  Phase 3 completed for cancers             | [DB01041](https://www.drugbank.ca/drugs/DB01041)             | Clinical Trial                                  | [26](https://clinicaltrials.gov/ct2/show/NCT04273529)        |
| Fingolimod            | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_fingolimod.png) |                                                              | COVID-19 Phase 2; Phase 4 completed for Multiple Sclerosis   | [DB08868](https://www.drugbank.ca/drugs/DB08868)             | Clinical Trial                                  | [27](https://clinicaltrials.gov/ct2/show/NCT04280588)        |
| Triazavirin           | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_triazavirin.png) | RNA synthesis inhibitor                                      | COVID-19 Phase 3                                             | [DB15622](https://www.drugbank.ca/drugs/DB15622)             | Clinical Trial                                  | [29](http://www.chictr.org.cn/showprojen.aspx?proj=49723)    |
| Tranilast             | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_tranilast.png) | Hematopoietic prostaglandin D synthase inhibitor             | Phase 4 completed for Conjunctivitis; COVID-19 Phase 4       | [DB07615](https://www.drugbank.ca/drugs/DB07615)             | Clinical Trial                                  | [30](http://www.chictr.org.cn/showprojen.aspx?proj=49738)    |
| Acetylcysteine        | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_acetylcysteine.png) | Mucolytic agent                                              | Phase 4 completed for Drug Overdose, AMI, Bipolar disorder, lung diseases; COVID-19 Phase 4 | [DB06151](https://www.drugbank.ca/drugs/DB06151)             | Clinical Trial                                  | [31](http://www.chictr.org.cn/showprojen.aspx?proj=50241)    |
| Ebastine              | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_ebastine.png) | H1 inhibitor                                                | Phase 4 completed for IBS, urticaria; COVID-19 Phase 4       | [DB11742](https://www.drugbank.ca/drugs/DB11742)             | Clinical Trial                                  | [32](http://www.chictr.org.cn/showprojen.aspx?proj=49790)    |
| Losartan              | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_losartan.png) | Angiotensin II receptor blocker                              | Phase 4 completed for high blood pressure, hypertension, diabetes mellitus, kidney diseases, stroke; COVID-19 Phase 2 | [DB00678](https://www.drugbank.ca/drugs/DB00678)             | Clinical Trial                                  | [33](https://clinicaltrials.gov/ct2/show/NCT04311177)        |
| Pirfenidone           | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_pirfenidone.png) | Collagen synthesis inhibitor, Profibrotic cytokine down-regulator | Phase 4 completed for IPF; Phase 3 completed for DFU; COVID-19 Phase 0 | [DB04951](https://www.drugbank.ca/drugs/DB04951)             | Clinical Trial                                  | [34](http://www.chictr.org.cn/showprojen.aspx?proj=51416)    |
| Camostat              | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_camostat.png) |                                                              | COVID-19 Phase I                                             | [DB13737](https://www.drugbank.ca/drugs/DB13729)             | Clinical Trial                                  | [35](https://clinicaltrials.gov/ct2/show/NCT04321096)        |



---

## COVID-19 pre-clinical studies 

We are making our best efforts to collect SARS-CoV-2 in vitro experimental results from various sources. This dataset will be updated continuously.

|  ﻿Drug Name  | Experimental Activities  | EC50/IC50(μM)  | CC50(μM)  | SI  | 
| ---- | --- | --- | --- | --- | 
|  Remdesivir  | SARS-CoV-2 inhibition  | 0.77  | >100  | >129.87  | 
|  Chloroquine  | SARS-CoV-2 inhibition  | 1.13  | >100  | >88.5  | 
|  Nitazoxanide  | SARS-CoV-2 inhibition  | 2.12  | 35.53  | >16.76  | 
|  Chlorpromazine Hydrochloride  | SARS-CoV-2 inhibition  | 4.03  | 11.88  | 2.94  | 
|  Amodiaquin Dihydrochloride Dihydrate  | SARS-CoV-2 inhibition  | 4.94  | 34.42  | 6.97  | 
|  CVL218  | SARS-CoV-2 inhibition  | 5.12  | 91.05  | 17.78  | 
|  Imatinib Mesylate  | SARS-CoV-2 inhibition  | 5.32  | >30.86  | >5.80  | 
|  Fluspirilene  | SARS-CoV-2 inhibition  | 5.32  | 30.33  | 5.71  | 
|  Amodiaquin Hydrochloride  | SARS-CoV-2 inhibition  | 5.64  | >38.63  | >6.84  | 
|  Triparanol  | SARS-CoV-2 inhibition  | 6.41  | 21.21  | 3.31  | 
|  Clomipramine Hydrochloride  | SARS-CoV-2 inhibition  | 7.59  | >29.68  | >3.91  | 
|  Thiethylperazine Maleate  | SARS-CoV-2 inhibition  | 8.02  | 18.37  | 2.29  | 
|  Mefloquine Hydrochloride  | SARS-CoV-2 inhibition  | 8.06  | 18.53  | 2.3  | 
|  Fluphenazine Dihydrochloride  | SARS-CoV-2 inhibition  | 8.98  | 20.02  | 2.23  | 
|  Tamoxifen Citrate  | SARS-CoV-2 inhibition  | 8.98  | 37.96  | 4.23  | 
|  Promethazine Hydrochloride  | SARS-CoV-2 inhibition  | 10.44  | >42.59  | >4.08  | 
|  Hydroxychloroquine Sulfate  | SARS-CoV-2 inhibition  | 11.17  | >50  | >4.48  | 
|  Toremifene Citrate  | SARS-CoV-2 inhibition  | 11.3  | 20.51  | 1.81  | 
|  Terconazole Vetranal  | SARS-CoV-2 inhibition  | 16.14  | 41.46  | 2.57  | 
|  Benztropine Mesylate  | SARS-CoV-2 inhibition  | 17.79  | >50  | >2.81  | 
|  Nafamostat  | SARS-CoV-2 inhibition  | 22.5  | >100  | >4.44  | 
|  Chloroquine Phosphate  | SARS-CoV-2 inhibition  | 46.8  | >50  | >1.07  | 
|  Favipiravir  | SARS-CoV-2 inhibition  | 61.88  | >400  | >6.46  | 
|  Penciclovir  | SARS-CoV-2 inhibition  | 95.96  | >400  | >4.17  | 
|  Ribavirin  | SARS-CoV-2 inhibition  | 109.5  | >400  | >3.65  | 

[Data Download](https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/COVID19_invitro_assays.csv)

Reference:
1.[Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research, 2020, 30(3): 269-271.](https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w))
2.[A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. bioRxiv, 2020.](https://www.biorxiv.org/content/10.1101/2020.03.11.986836v1.abstract)
3.[FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro. bioRxiv, 2020.](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)


<br>

<br>

<br>

Your [**feedback**](https://github.com/GHDDI-AILab/Targeting2019-nCoV/issues) is highly appreciated.

